Announcement on Annual Earnings Preannouncement for 2024
Filed with SSE · · 2 pages · Chinese
CanSino Biologics, Inc. on 6ix
Earlier from CanSino Biologics
- Announcement on the Voluntary Disclosure of the Obtaining of the Registration Certificate in Indonesia for the Group ACYW135 Meningococcal Polysaccharide Conjugate Vaccine (CRM197 Vector)
- Announcement on Voluntary Disclosure of Initiation of Phase II/III Clinical Trial for Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed (for Population Aged 6 and Above) and Completion of First Subject Enrollment in Phase II Clinical Trial
- Announcement of the Acceptance of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children
- Indicative Announcement on the Termination of Partial Shareholders' Concerted Action Relationship and Changes in Equity
- Indicative Announcement on One of Actual Controllers Adjusting H-share Holding Method and Signing Supplementary Agreement (II) to Concerted Action Agreement
Later from CanSino Biologics
- Announcement on Voluntary Disclosure of Acceptance of Drug Registration Application for Adsorbed Tetanus Vaccine
- Announcement on Voluntary Disclosure of Formal Inclusion of the Drug Registration Application for the "Diphtheria, Tetanus and Acellular Pertussis (Component) Combined Vaccine, Adsorbed" for Infants and Young Children in Priority Review Varieties
- Announcement on Obtaining the Approval Notice for Drug Clinical Trials of Adsorbed Acellular Pertussis (Components), Tetanus, Diphtheria, Haemophilus Influenzae Type b (Conjugate), and Meningococcal Group ACYW135 (Conjugate) Combined Vaccine
- Announcement on Preliminary Earnings Estimate for 2024
- Announcement on Renewing Engagement of Accounting Firm
Follow CanSino Biologics into a list and get an email when it puts out news.
Follow CanSino Biologics